High-Dose Cyclophosphamide for Moderate to Severe Refractory Multiple Sclerosis

Abstract

Background: High-dose cyclophosphamide is active in immune-mediated illnesses.Objective: To describe the effects of high-dose cyclophosphamide on severe refractory multiple sclerosis.

High‐Dose Cyclophosphamide in the Treatment of Multiple Sclerosis

“…Our results are similar to the findings reported from the Krishnan study in regard to relapsing remitting patients [42]. It also confirmed results of Gladstone's trial, but with longer patient follow-ups we are able to demonstrate a prolonged response to treatment [43]. HDC is well tolerated, has a good safety profile, and a long history of beneficial use [32][33][34]44].…”

High‐Dose Cyclophosphamide in the Treatment of Multiple Sclerosis

“…Our results are similar to the findings reported from the Krishnan study in regard to relapsing remitting patients [42]. It also confirmed results of Gladstone's trial, but with longer patient follow-ups we are able to demonstrate a prolonged response to treatment [43]. HDC is well tolerated, has a good safety profile, and a long history of beneficial use [32][33][34]44].…”

Treatment of relapsing–remitting multiple sclerosis with high-dose cyclophosphamide induction followed by glatiramer acetate maintenance

“…In this review, there were no cases of mortality and minimal morbidity. This is similar to prior reports on the use of HiCy in MS. [6][7][8]17 As expected, infections were common, occurring in 47% of patients. However, there was only one case of sepsis, and no longterm morbidity from these infections was noted.…”

Reduction of Disease Activity and Disability With High-Dose Cyclophosphamide in Patients With Aggressive Multiple Sclerosis

“…This study examined radiologic and clinical fea-tures not previously studied and had a longer follow-up (23 months) than previously published. 26 We found that HiCy treatment induced a significant reduction in disease activity and disability in most patients. Some patients experienced sustained remission of all detectable disease activity despite receiving no subsequent immunomodulatory therapy.…”

High‐Dose Cyclophosphamide in the Treatment of Multiple Sclerosis

“…Our results are similar to the findings reported from the Krishnan study in regard to relapsing remitting patients [42]. It also confirmed results of Gladstone's trial, but with longer patient follow-ups we are able to demonstrate a prolonged response to treatment [43]. HDC is well tolerated, has a good safety profile, and a long history of beneficial use [32][33][34]44].…”

Treatment of relapsing–remitting multiple sclerosis with high-dose cyclophosphamide induction followed by glatiramer acetate maintenance

“…In this review, there were no cases of mortality and minimal morbidity. This is similar to prior reports on the use of HiCy in MS. [6][7][8]17 As expected, infections were common, occurring in 47% of patients. However, there was only one case of sepsis, and no longterm morbidity from these infections was noted.…”

Reduction of Disease Activity and Disability With High-Dose Cyclophosphamide in Patients With Aggressive Multiple Sclerosis

“…This study examined radiologic and clinical fea-tures not previously studied and had a longer follow-up (23 months) than previously published. 26 We found that HiCy treatment induced a significant reduction in disease activity and disability in most patients. Some patients experienced sustained remission of all detectable disease activity despite receiving no subsequent immunomodulatory therapy.…”

High‐Dose Cyclophosphamide in the Treatment of Multiple Sclerosis

“…Our results are similar to the findings reported from the Krishnan study in regard to relapsing remitting patients [42]. It also confirmed results of Gladstone's trial, but with longer patient follow-ups we are able to demonstrate a prolonged response to treatment [43]. HDC is well tolerated, has a good safety profile, and a long history of beneficial use [32][33][34]44].…”

Treatment of relapsing–remitting multiple sclerosis with high-dose cyclophosphamide induction followed by glatiramer acetate maintenance

“…In this review, there were no cases of mortality and minimal morbidity. This is similar to prior reports on the use of HiCy in MS. [6][7][8]17 As expected, infections were common, occurring in 47% of patients. However, there was only one case of sepsis, and no longterm morbidity from these infections was noted.…”

Reduction of Disease Activity and Disability With High-Dose Cyclophosphamide in Patients With Aggressive Multiple Sclerosis

“…This study examined radiologic and clinical fea-tures not previously studied and had a longer follow-up (23 months) than previously published. 26 We found that HiCy treatment induced a significant reduction in disease activity and disability in most patients. Some patients experienced sustained remission of all detectable disease activity despite receiving no subsequent immunomodulatory therapy.…”